Technology story teller | Keeping an eye on trends & competitors to follow their extraordinary technological tale📈 Entrepreneur at heart.
Joined August 2022
- Tweets3.6K
- Following2K
- Followers2K
- Likes17.7K
wonder why
JUST IN: SpaceX, Tesla, Amazon, & Netflix now oppose having their stocks tokenized through OKX and ICE markets, bringing the total to 56 companies.
• Dell
• IBM
• Intel
• Nike
• IREN
• IonQ
• AMD
• Intuit
• Tesla
• Nvidia
• Netflix
• Adobe
• Oracle
• Reddit
• Eli Lilly
• Costco
• Verizon
• SpaceX
• Corning
• Sandisk
• Carnival
• Amazon
• Walmart
• Moderna
• Alphabet
• AppLovin
• Microsoft
• JPMorgan
• Broadcom
• Caterpillar
• Coca-Cola
• Qualcomm
• Rocket Lab
• CoreWeave
• Wells Fargo
• McDonald's
• CrowdStrike
• Cigna Group
• Arm Holdings
• Bloom Energy
• Lam Research
• Applied Digital
• Arcos Dorados
• Cisco Systems
• Western Digital
• USA Rare Earth
• Goldman Sachs
• Applied Materials
• SoFi Technologies
• Cerebras Systems
• Micron Technology
• Palo Alto Networks
• Marvell Technology
• UnitedHealth Group
• Applied Optoelectronics
• Hewlett Packard Enterprise
HELLO WALL STREET
bottom is in
trade[XYZ] and ICE, owner of the New York Stock Exchange, are joining forces to bring 24/7 perpetual futures on Hyperliquid to the United States.
In just over a year, our markets on Hyperliquid have surpassed $650 billion in volume. They provide continuous price discovery for stocks, indices, and commodities, and have become trusted reference points for retail and institutions alike when traditional markets are closed. Much of the world trades them. Until now, Americans could only watch.
We intend to change that. Subject to CFTC approval, trade[XYZ] and ICE plan to establish a new, dedicated U.S. market, with novel exchange and clearing infrastructure built on Hyperliquid. Planned contracts span equities, indices, commodities, FX, and crypto, with access through participating brokers and platforms. We’ll share more on products, eligibility, and timing as approvals progress.
ICE brings more than 25 years of experience operating regulated markets, clearing, and managing risk. trade[XYZ] brings the product development, market design, and technology behind the most liquid and robust markets on Hyperliquid.
Innovation and the protections of U.S. regulation shouldn’t be a trade-off. Together, we plan to prove it.
ICE is making a strategic investment in trade[XYZ] and joins us in building towards the future of Hyperliquid. A small group of market luminaries is joining as well, beginning with Stan Druckenmiller. For more than four decades, few investors have anticipated the great turns in markets as often as Stan. We’re proud to have him with us for the next one.
We’re building the U.S. market in parallel with our existing HIP-3 markets, which we’ll continue to expand and innovate on. We expect both to flourish. They each have a long road map ahead, from new asset classes to new ways to trade them.
To the Hyperliquid community, whether you were here before us or came because of us, thank you. You took a chance on new markets and you made them matter. You’ll forever be a part of this story.
Anything. Anytime. On ICE[XYZ].
1-person billion-dollar companies are going to become the norm
Surprise 1: Anthropic acquired a one-person biotech
.
.
.
Surprise 2: that person is me
Surprise 3: I’m here to tell you all about it
Yes, this is what you think it is; after 6 yrs of increasingly loose anonymity: the Professor Oak reveal post
…and yes, it has gotten so boring around here that I’m literally doxxing myself to spice up the timeline
-------
Ok, allow me to introduce myself. My name is Cody Tranbarger. I mostly tweet, but occasionally find time to dabble in drug dev & starting/building biotechs. My past lives span the VC, crossover, startup continuum; Prof Oak has been my way of keeping a digital foot in those worlds, despite having my physical feet planted elsewhere.
The past 18 mo, ‘elsewhere’ was Mithril Medicine, a co. I founded to develop bsAbs for LAMA2-CMD & other ECM-related genetic diseases.
Mithril was born out of hands-on building with @MikeNGladstone, @JasonPaulRhodes, @LifeSciVC, & team @atlasventure. Somehow, I made enough half-decent calls along the way (even a broken clock is right twice a day, eh?) to convince them Mithril/I warranted a small seed. While I can hardly rationalize such an outrageously cavalier bet, I’m grateful for it, & I'd partner with Atlas again in a heartbeat.
In typical AV fashion, Mithril’s primordial form was virtual, decentralized, & ultra-lean. This stage tends to be short-lived, but for Mithril, it worked surprisingly well, for surprisingly long, thanks in part to the rapid maturation of the AI tools I used liberally.
Eventually, Mithril became a bit of an experiment itself - to find the upper bound of how far it could scale as a single operator + a bunch of Claude (+ a stellar bench of part-time consultants).
In parallel, I started spending time with @nc_frey, @an1lam, & @CoefficientBio team; and promptly experienced, for the 1st time, AI at the frontier. Soon thereafter, Mithril stopped looking like an experiment, & started looking like a preview of an entirely new operating model.
From that spark came “Pipeline-in-a-Person.” The idea immediately resonated when we shared it here back in April; and it was central to the shared vision that led to Anthropic’s acquisition of Mithril, & my joining the team.
Why join Anthropic? Three reasons.
(1) For Mithril, the programs continue, with more resources & infrastructure behind them, and as much Claude as I can put to work.
(2) For me, the chance to start several more programs, & find out how many one person can actually run in parallel - an almost unprecedented luxury for a curious drug hunter.
(3) For our mission, a path to institutionalize & scale this new way of working, then put it in the hands of all of biopharma, all over the world - which, candidly, I find the most energizing.
Will AI x Bio cure diseases? Unequivocally yes, imo… but not by the route that gets the most airtime. Rather than timeline acceleration & compression, I see orchestration & parallelization as today's low-hanging fruit.
Most drug hunters see a handful of go/no-go calls in a career, & spend entirely too much of the rest trading emails (my inbox can attest).
Give them the bandwidth to run several programs at once, and the time to focus on scientific judgment, and I’m willing to bet they’ll make better calls. And at scale, better calls translate to more drugs, higher hit rates, broader patient impact, & likely, a disease or 10 or 100 cured. I couldn't be more excited to build toward that future @AnthropicAI.
Finally, a heartfelt thank you to BioTwitter/X. The end of anonymity is bittersweet, but if anyone’s earned a proper introduction, you all have.
It’s difficult to overstate how much this app has done for me: a decade of education, plenty of friends, many job opportunities, several mentors, a few investors, even a co-founder (fmr). It was the generosity of this community that inspired me to start posting 6 years ago, after just as many years lurking. I hope I’ve been able to pay it forward, in my own small way.
But, to be clear, Prof Oak isn’t going anywhere. Same beat, same themes, and now, a front-row seat to drug development at the frontier. Stay tuned for dispatches from the trenches; and remember...
Gotta Cure 'Em All
she what????
BREAKING: The White House says Melania Trump has brokered a ceasefire between Russia and Ukraine "localised to the city of Oleshky".
trib.al/XIIDIrN
📺 Sky 501, Virgin 602, Freeview 233 and YouTube
Its my @Muse its chill
maybe people will finally start to care about cyber attacks
An urgent notice from the Railway team
blog.railway.com/p/security-…
4
40
4,910
about to have my @Muse go out and look for fraud for that 1% 😈
See fraud? It's time to expose it.
Report fraud, waste, and abuse to the federal government 📲 America.gov/fraud
My kids only watch YouTube these days cause netflix just ain't it anymore
This tracks. I watch something on YouTube every day. Netflix is a dormant subscription for me.
YouTube has very low costs of content creation. Netflix has $14B of debt that has financed their content library.
Another lesson in the halls of mismatching assets and liabilities? Time will tell.
4
43
4,974
sad sad sad
What’s happening in Paris and Milan is no surprise to anyone who has spent time around young people in Europe during the 2010s:
Virtually all of them were working on their 4th masters degree in social welfare, were unmarried, attended communist dinners every night, and regularly participated in riots.
Now the economy is suddenly transforming and they have nothing to show for it.